Menu Search
Equities

Avricore Health Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8VP1:FRA

Avricore Health Inc

Actions
  • Price (EUR)0.0405
  • Today's Change0.003 / 8.00%
  • Shares traded--
  • 1 Year change+47.27%
  • Beta0.2163
Data delayed at least 15 minutes, as of Feb 13 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies. HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The Company offers tests for approximately 27 biomarkers with a focus on screening and managing chronic conditions, such as diabetes, heart disease and chronic kidney disease, as well as checking for common viral and bacterial infections. Its test menu includes total cholesterol, triglycerides, FRS, HbA1c, glucose, sodium, potassium, calcium, chloride, total CO2, COVID-19, Flu A, Flu B, and Strep A.

  • Revenue in CAD (TTM)1.92m
  • Net income in CAD-1.63m
  • Incorporated2000
  • Employees--
  • Location
    Avricore Health Inc1120 - 789 West Pender StreetVANCOUVER V6C 1H2CanadaCAN
  • Phone+1 (604) 773-8943
  • Fax+1 (604) 687-2038
  • Websitehttps://avricore.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.